
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is an attractive investment opportunity due to the potential approval and commercialization of VS-7375 for 2L+ NSCLC and 2L+ PDAC, strong efficacy and manageable side effects of the drug in treating LGSOC, and potential combination treatments. However, there are risks involved with clinical trials and competition, and the company is planning a secondary offering to fund development. Overall, prospects for VS-7375 are positive, but investors must carefully watch for any setbacks in trials and competitive developments.
Bears say
Verastem is currently in the late stages of developing novel anticancer treatments, particularly focused on RAF/MEK and FAK inhibition. While preliminary anti-tumor activity has been observed in 2L-3L advanced NSCLC patients at the monotherapy dose of 600 mg, the data remain limited and only one patient has had more than 6 months of follow-up. Additionally, the expected completion of enrollment in 2026 and the evaluation of different treatment combinations suggest potential delays in bringing these treatments to market and achieving significant profitability.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares